Susquehanna International Group’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $123K | Buy |
123,998
+41,524
| +50% | +$49.4K | ﹤0.01% | 12197 |
|
|
2025
Q4 | $112K | Sell |
82,474
-22,966
| -22% | -$33.5K | ﹤0.01% | 11392 |
|
|
2025
Q3 | $169K | Buy |
105,440
+22,368
| +27% | +$36.4K | ﹤0.01% | 11163 |
|
|
2025
Q2 | $116K | Sell |
83,072
-23,910
| -22% | -$35.8K | ﹤0.01% | 11696 |
|
|
2025
Q1 | $172K | Buy |
106,982
+75,043
| +235% | +$95.3K | ﹤0.01% | 11097 |
|
|
2024
Q4 | $40.2K | Buy |
31,939
+9,451
| +42% | +$14.7K | ﹤0.01% | 11759 |
|
|
2024
Q3 | $42.3K | Sell |
22,488
-18,221
| -45% | -$72K | ﹤0.01% | 11441 |
|
|
2024
Q2 | $301K | Sell |
40,709
-56,623
| -58% | -$466K | ﹤0.01% | 9439 |
|
|
2024
Q1 | $762K | Buy |
97,332
+36,336
| +60% | +$234K | ﹤0.01% | 7515 |
|
|
2023
Q4 | $310K | Sell |
60,996
-13,229
| -18% | -$68.1K | ﹤0.01% | 9768 |
|
|
2023
Q3 | $439K | Buy |
74,225
+7,076
| +11% | +$47.1K | ﹤0.01% | 8533 |
|
|
2023
Q2 | $498K | Sell |
67,149
-177,729
| -73% | -$1.51M | ﹤0.01% | 8325 |
|
|
2023
Q1 | $2.31M | Buy |
244,878
+95,425
| +64% | +$1.01M | ﹤0.01% | 4828 |
|
|
2022
Q4 | $1.59M | Buy |
149,453
+137,316
| +1,131% | +$1.39M | ﹤0.01% | 5152 |
|
|
2022
Q3 | $90K | Sell |
12,137
-43,828
| -78% | -$272K | ﹤0.01% | 11779 |
|
|
2022
Q2 | $269K | Buy |
55,965
+20,400
| +57% | +$116K | ﹤0.01% | 9857 |
|
|
2022
Q1 | $181K | Buy |
+35,565
| New | +$187K | ﹤0.01% | 11356 |
|
|
2021
Q3 | – | Sell |
-22,033
| Closed | -$153K | – | 12708 |
|
|
2021
Q2 | $174K | Buy |
22,033
+2,478
| +13% | +$19.4K | ﹤0.01% | 11731 |
|
|
2021
Q1 | $149K | Sell |
19,555
-28,086
| -59% | -$239K | ﹤0.01% | 11658 |
|
|
2020
Q4 | $372K | Buy |
47,641
+27,710
| +139% | +$301K | ﹤0.01% | 8866 |
|
|
2020
Q3 | $193K | Buy |
19,931
+16,057
| +414% | +$177K | ﹤0.01% | 9479 |
|
|
2020
Q2 | $41K | Buy |
3,874
+1,681
| +77% | +$12.7K | ﹤0.01% | 9798 |
|
|
2020
Q1 | $12K | Buy |
+2,193
| New | +$15.6K | ﹤0.01% | 10017 |
|
|
2019
Q4 | – | Sell |
-369
| Closed | -$3K | – | 9680 |
|
|
2019
Q3 | $3K | Sell |
369
-1,966
| -84% | -$13.7K | ﹤0.01% | 10057 |
|
|
2019
Q2 | $17K | Buy |
+2,335
| New | +$23.5K | ﹤0.01% | 10022 |
|
|
2019
Q1 | – | Sell |
-3,059
| Closed | -$36K | – | 8786 |
|
|
2018
Q4 | $36K | Buy |
+3,059
| New | +$52.2K | ﹤0.01% | 8571 |
|
|
2017
Q1 | – | Sell |
-1,086
| Closed | -$41.7K | – | 8904 |
|
|
2016
Q4 | $29K | Buy |
1,086
+183
| +20% | +$5.73K | ﹤0.01% | 9381 |
|
|
2016
Q3 | $37K | Buy |
903
+199
| +28% | +$10.2K | ﹤0.01% | 8190 |
|
|
2016
Q2 | $37K | Sell |
704
-366
| -34% | -$20.4K | ﹤0.01% | 8291 |
|
|
2016
Q1 | $64K | Sell |
1,070
-740
| -41% | -$46.7K | ﹤0.01% | 8596 |
|
|
2015
Q4 | $175K | Sell |
1,810
-501
| -22% | -$33.3K | ﹤0.01% | 8526 |
|
|
2015
Q3 | $123K | Buy |
2,311
+312
| +16% | +$20.8K | ﹤0.01% | 9034 |
|
|
2015
Q2 | $159K | Buy |
+1,999
| New | +$171K | ﹤0.01% | 9456 |
|
Other funds holding ATNM
VCM
GS
VFT
Susquehanna International Group's ATNM Position: Q1 2026 in Review
Susquehanna International Group increased its Actinium Pharmaceuticals (ATNM) stake by 50% in Q1 2026, buying an estimated $49.4K and bringing the position to 123,998 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #12197.
Susquehanna International Group first reported a position in ATNM in Q2 2015 and has held it in 33 quarters since. The position peaked at $2.31M in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.
- Susquehanna International Group held 123,998 shares of Actinium Pharmaceuticals worth $123K as of Q1 2026.
- Susquehanna International Group bought 41,524 Actinium Pharmaceuticals shares in Q1 2026, an estimated $49.4K.
- Actinium Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12197 holding.
- Susquehanna International Group first reported a position in Actinium Pharmaceuticals in Q2 2015 and has held it in 33 quarters since.
- Susquehanna International Group's Actinium Pharmaceuticals position peaked at $2.31M in Q1 2023.
- 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.